



Celltrion CONNECT® Patient Support Program (PSP) can help you understand health insurance coverage requirements, answer billing and coding questions, and enroll eligible patients in all program services, including financial assistance programs, helping to secure appropriate access to VEGZELMA® (bevacizumab-adcd) for eligible patients.

Enroll your patients into Celltrion CONNECT®

Services include benefits verification, prior authorization assistance, and co-pay assistance.



Visit the online portal via go.covermymeds.com/ CelltrionCONNECT to complete and submit the Digital Enrollment form



Visit: www.CelltrionConnect.com to access the enrollment form and fax to: 614-633-2259

Celltrion CARES™ Co-pay Assistance Program

With the Celltrion CARES[™] Co-pay Assistance Program, patients with private/commercial insurance may be eligible to receive co-pay savings for VEGZELMA.



Eligible patients with private/ commercial insurance may pay as little as \$0 per month



Celltrion CARES[™] helps to reimburse patient's out of pocket expenses, up to \$25,000 per calendar year*⁺



Enroll directly into the Celltrion CARES[™] Co-pay Assistance Program: www.CelltrionCares.com

For more information, call 1-877-812-6662 (1-877-81CONNC) Monday–Friday, 8 AM–8 PM EST, or visit <u>www.CelltrionConnect.com</u>

* Other terms and conditions apply. Visit: www.CelltrionConnect.com for full eligibility criteria.

† The program is not valid for prescriptions that are eligible to be reimbursed, in whole or in part, by Medicaid (including Medicaid patients enrolled in a qualified health plan purchased through a health insurance exchange [marketplace] established by a state government or the federal government), Medicare, a Medicare Part D or Medicare Advantage plan (regardless of whether a specific prescription is covered), TRICARE, CHAMPUS, Puerto Rico Government Health Insurance Plan ("Healthcare Reform"), or any other state or federal medical or pharmaceutical benefit program or pharmaceutical assistance program (collectively, "Government Programs").







Celltrion CONNECT® Patient Assistance Program (PAP) Patients who are uninsured, underinsured, or lack coverage may be eligible to receive VEGZELMA at no cost. Patient eligibility criteria, including household income limits, and program conditions apply. Celltrion CONNECT® can help evaluate patients' eligibility for assistance.

Access and Reimbursement



Benefits Investigation Addresses:

- How VEGZELMA will be covered under your patient's health plan
- Additional coverage information to facilitate your patient's access to VEGZELMA



Celltrion CONNECT® Case Managers:

- Prior authorization (PA) support to review and explain payer requirements
- Appeal assistance
- Claims assistance

Additional Celltrion CONNECT® Support

6	កា
Ч —	
$\perp =$	ᆘᄲ
· · · · · ·	
- <u>1</u>	ᄟ
Ŷ	
+	
Q.	П

Billing & Coding Guide

to provide information about relevant codes for VEGZELMA

٢	Â
	Ĥ
Ľ	

Sample Reimbursement Letters

Outline medical necessity guidelines or appeal requirements to create your own letters

1		+
1		
F		
	<u> </u>	Ċ

Billing and Coding Tip Sheets

Billing and coding information sheets to assist healthcare providers with understanding coding for each VEGZELMA indication, a biosimilar approved for use in the United States. Here are the indications with a corresponding tip sheet:

- Cervical Cancer
- Globlastoma
- Metastatic Colorectal Cancer (mCRC)
- Metastatic Renal Cell Carcinoma (mRCC)
- Non-Small Cell Lung Cancer (NSCLC)
- Ovarian, Fallopian Tube, and Peritoneal Cancer

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see the full Prescribing Information here.

Celltrion CONNECT® is a registered trademark of Celltrion Holdings, Co., Ltd., used under license. Celltrion CARES™ is a trademark of Celltrion Holdings, Co., Ltd., used under license. VEGZELMA® is a registered trademark of Celltrion, Inc., used under license. ©Celltrion USA, Inc. 2023 OTH-2304-2403-CM027 05/23